{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:20Z","timestamp":1786985420401,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bmc.2023.117242","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T21:51:30Z","timestamp":1679089890000},"page":"117242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Design, synthesis and bioactivity evaluations of 8-substituted-quinoline-2-carboxamide derivatives as novel histone deacetylase (HDAC) inhibitors"],"prefix":"10.1016","volume":"85","author":[{"given":"Yunpeng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wandi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuben","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengda","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2023.117242_b0005","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117242_b0010","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/acschembio.7b00321","article-title":"Comparison of the Deacylase and Deacetylase Activity of Zinc-Dependent HDACs","volume":"12","author":"McClure","year":"2017","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmc.2023.117242_b0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.molcel.2008.07.002","article-title":"Lysine acetylation: Codified crosstalk with other posttranslational modifications","volume":"31","author":"Yang","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmc.2023.117242_b0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-642-21631-2_3","article-title":"Deacetylation of nonhistone proteins by HDACs and the implications in cancer","volume":"206","author":"Peng","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.bmc.2023.117242_b0025","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","article-title":"Clinical Studies of Histone Deacetylase Inhibitors","volume":"15","author":"Prince","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2023.117242_b0030","first-page":"13","article-title":"Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives","author":"Jenke","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2023.117242_b0035","first-page":"277","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","author":"Ramaiah","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.bmc.2023.117242_b0040","doi-asserted-by":"crossref","unstructured":"New M, Olzscha H, Thangue NLJMO, HDAC inhibitor-based therapies: can we interpret the code?, 2012; 6: 637\u2013656.","DOI":"10.1016\/j.molonc.2012.09.003"},{"key":"10.1016\/j.bmc.2023.117242_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.combustflame.2016.05.008","article-title":"Onset mechanism of primary acoustic instability in downward-propagating flames","volume":"170","author":"Yoon","year":"2016","journal-title":"Combust Flame"},{"key":"10.1016\/j.bmc.2023.117242_b0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/14756366.2020.1835883","article-title":"Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines","volume":"36","author":"Nencetti","year":"2021","journal-title":"J Enzyme Inhibit Med Chem"},{"key":"10.1016\/j.bmc.2023.117242_b0055","first-page":"28","article-title":"Synthesis and biological evaluation of 2-quinolineacrylamides","author":"Wang","year":"2020","journal-title":"Bioorganic Med Chem"},{"key":"10.1016\/j.bmc.2023.117242_b0060","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/14756366.2020.1839446","article-title":"Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms","volume":"36","author":"Mehndiratta","year":"2021","journal-title":"J Enzyme Inhibit Med Chem"},{"key":"10.1016\/j.bmc.2023.117242_b0065","first-page":"211","article-title":"Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors","author":"Avelar","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117242_b0070","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1021\/jm9004303","article-title":"Discovery of a Potent Class I Selective Ketone Histone Deacetylase Inhibitor with Antitumor Activity in Vivo and Optimized Pharmacokinetic Properties","volume":"52","author":"Kinzel","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117242_b0075","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acs.jmedchem.7b01404","article-title":"(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo","volume":"61","author":"Lee","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117242_b0080","doi-asserted-by":"crossref","first-page":"112651","DOI":"10.1016\/j.ejmech.2020.112651","article-title":"Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors","volume":"204","author":"Hu","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117242_b0085","doi-asserted-by":"crossref","first-page":"103970","DOI":"10.1016\/j.bioorg.2020.103970","article-title":"Discovery of novel dual c-Met\/HDAC inhibitors as a promising strategy for cancer therapy","volume":"101","author":"Hu","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2023.117242_b0090","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.1021\/jm101177s","article-title":"Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor","volume":"53","author":"Moffat","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117242_b0095","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1158\/1078-0432.CCR-11-3165","article-title":"A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors","volume":"18","author":"Banerji","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2023.117242_b0100","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1016\/j.bmc.2015.06.024","article-title":"Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors","volume":"23","author":"Wang","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2023.117242_b0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2017.03.064","article-title":"Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors","volume":"133","author":"Chen","year":"2017","journal-title":"Eur J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623000901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623000901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:22:17Z","timestamp":1760836937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089623000901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":21,"alternative-id":["S0968089623000901"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117242","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and bioactivity evaluations of 8-substituted-quinoline-2-carboxamide derivatives as novel histone deacetylase (HDAC) inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117242"}}